Preclinical Evaluation and First-in-Human Imaging with 18 F-NOTA-R49: A Comparative Analysis versus 18 F-FDG PET/CT in Various Cancer Patients
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01742 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Guanyun Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing 100050, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Neoplasms, Fluorine Radioisotopes. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Major Science and Technology Projects of China, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Our study aims to develop a novel 18F-labeled fibroblast activation protein inhibitor (FAPI) probe, 18F-NOTA-R49, and validate its diagnostic performance across multiple cancers in both preclinical and clinical studies. 18F-NOTA-R49 was synthesized through chemical methods, and its in vitro affinity, internalization characteristics, and specificity were evaluated in FAP-overexpressing cells HEK-293-hFAP and U-87 MG. Tumor-bearing mouse models were established to assess in vivo targeting and pharmacokinetics via small-animal PET/CT imaging and biodistribution studies. Ten patients with various cancers were enrolled in a clinical study comparing lesion-detection capabilities of 18F-NOTA-R49 and 18F-FDG PET/CT. In vivo studies showed significant early uptake in FAP-positive tumors (29.36 ± 1.49%ID/g at 0.5 h), which was effectively blocked by unlabeled NOTA-R49. Clinically, 18F-NOTA-R49 exhibited superior lesion contrast compared to 18F-FDG in gastric cancer, mesenchymal tumors, prostate cancer, seminoma, and pancreatic cancer, particularly in peritoneal and lymph node metastases. 18F-NOTA-R49 demonstrates high affinity and specificity and excellent tumor-targeting properties. It shows better diagnostic efficacy than 18F-FDG in various malignant tumors, indicating a significant clinical translation potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing 100050, China.
- Tianjin Hengrui Pharmaceutical Company, No. 39, First Avenue, Economic Development Zone, Dongli District, Tianjin 300300, China.
ORCID-Profile: Guanyun Wang
Förderung
- National Major Science and Technology Projects of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, G., Wen, X., Zheng, L., Ge, X., Zhang, K., Kan, Y., Zhang, M., Wang, W., Zhang, M., Guo, F., & Yang, J. (2026). Preclinical Evaluation and First-in-Human Imaging with 18 F-NOTA-R49: A Comparative Analysis versus 18 F-FDG PET/CT in Various Cancer Patients. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01742
Vancouver
Wang G, Wen X, Zheng L, Ge X, Zhang K, Kan Y, et al. Preclinical Evaluation and First-in-Human Imaging with 18 F-NOTA-R49: A Comparative Analysis versus 18 F-FDG PET/CT in Various Cancer Patients. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01742
BibTeX
@article{Wang2026,
author = {Wang, Guanyun and Wen, Xin and Zheng, Lingling and Ge, Xinyue and Zhang, Keyu and Kan, Ying and Zhang, Mengyi and Wang, Wei and Zhang, Mingyu and Guo, Feihu and Yang, Jigang},
title = {Preclinical Evaluation and First-in-Human Imaging with 18 F-NOTA-R49: A Comparative Analysis versus 18 F-FDG PET/CT in Various Cancer Patients},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01742}
}
EUVIMED